Asset Details
Do you wish to reserve the book?
Urologists' Use of Intensity-Modulated Radiation Therapy for Prostate Cancer
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Urologists' Use of Intensity-Modulated Radiation Therapy for Prostate Cancer
Do you wish to request the book?
Urologists' Use of Intensity-Modulated Radiation Therapy for Prostate Cancer
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Urologists' Use of Intensity-Modulated Radiation Therapy for Prostate Cancer
2013
Overview
Some urology groups have integrated intensity-modulated radiation therapy (IMRT) into their practice, which allows them to refer patients to their own practice for IMRT. This analysis showed a substantial increase in IMRT use by urologists who acquired ownership of IMRT services.
In 2011, nearly 240,900 men in the United States received a new diagnosis of prostate cancer.
1
Approximately 90% of these men had clinically localized disease, which was indolent in most cases. The relative 10-year survival rate among all men with prostate cancer is 98%.
1
,
2
Primary definitive treatments include prostatectomy, external-beam radiation therapy, and brachytherapy. Alternatively, the patient may opt for a less aggressive (monitoring) approach that includes active surveillance or hormone therapy. Table 1 describes each treatment option.
Despite substantial variation in reimbursement, evidence suggests that for low-risk disease, the three primary definitive treatments are clinically equivalent when measured in terms . . .
Publisher
Massachusetts Medical Society
Subject
Androgen Antagonists - therapeutic use
/ Biological and medical sciences
/ Gynecology. Andrology. Obstetrics
/ Humans
/ Male
/ Medicare
/ Men
/ Nephrology. Urinary tract diseases
/ Physician Self-Referral - statistics & numerical data
/ Prostatic Neoplasms - drug therapy
/ Prostatic Neoplasms - radiotherapy
/ Radiotherapy, Intensity-Modulated - economics
/ Radiotherapy, Intensity-Modulated - utilization
/ Referral and Consultation - statistics & numerical data
/ Self
/ Tumors
/ Tumors of the urinary system
